| Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer I Vergote, CG Tropé, F Amant, GB Kristensen, T Ehlen, N Johnson, ... New England Journal of Medicine 363 (10), 943-953, 2010 | 2579 | 2010 |
| A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women EA Joura, AR Giuliano, OE Iversen, C Bouchard, C Mao, J Mehlsen, ... New England Journal of Medicine 372 (8), 711-723, 2015 | 1612 | 2015 |
| Randomized intergroup trial of cisplatin–paclitaxel versus cisplatin–cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results MJ Piccart, K Bertelsen, K James, J Cassidy, C Mangioni, E Simonsen, ... Journal of the National Cancer Institute 92 (9), 699-708, 2000 | 1305 | 2000 |
| Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the … J Pfisterer, M Plante, I Vergote, A du Bois, H Hirte, AJ Lacave, U Wagner, ... Journal of Clinical Oncology 24 (29), 4699-4707, 2006 | 857 | 2006 |
| Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix R Pearcey, M Brundage, P Drouin, J Jeffrey, D Johnston, H Lukka, ... Journal of Clinical Oncology 20 (4), 966-972, 2002 | 645 | 2002 |
| 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG … A Du Bois, M Quinn, T Thigpen, J Vermorken, E Avall-Lundqvist, ... Annals of oncology 16, viii7-viii12, 2005 | 546 | 2005 |
| 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer GCE Stuart, H Kitchener, M Bacon, C Marth, T Thigpen, E Trimble Int J Gynecol Cancer 21 (4), 750-755, 2011 | 443 | 2011 |
| Reviews of evidence regarding interventions to reduce tobacco use and exposure to environmental tobacco smoke DP Hopkins, PA Briss, CJ Ricard, CG Husten, VG Carande-Kulis, ... American journal of preventive medicine 20 (2), 16-66, 2001 | 335 | 2001 |
| A brief mindfulness-based cognitive behavioral intervention improves sexual functioning versus wait-list control in women treated for gynecologic cancer LA Brotto, Y Erskine, M Carey, T Ehlen, S Finlayson, M Heywood, J Kwon, ... Gynecologic oncology 125 (2), 320-325, 2012 | 326 | 2012 |
| Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial GS Ogilvie, D van Niekerk, M Krajden, LW Smith, D Cook, L Gondara, ... Jama 320 (1), 43-52, 2018 | 284 | 2018 |
| Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical … K Swenerton, J Jeffrey, G Stuart, M Roy, G Krepart, J Carmichael, ... Journal of clinical oncology 10 (5), 718-726, 1992 | 281 | 1992 |
| Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials I Vergote, C Coens, M Nankivell, GB Kristensen, MKB Parmar, T Ehlen, ... The Lancet Oncology 19 (12), 1680-1687, 2018 | 253 | 2018 |
| Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: recurrent disease MK Wilson, E Pujade-Lauraine, D Aoki, MR Mirza, D Lorusso, AM Oza, ... Annals of Oncology 28 (4), 727-732, 2017 | 236 | 2017 |
| Clinical trials in recurrent ovarian cancer M Friedlander, E Trimble, A Tinker, D Alberts, E Avall-Lundqvist, M Brady, ... International Journal of Gynecologic Cancer 21 (4), 2011 | 230 | 2011 |
| Report of a National Workshop on Screening for Cancer of the Cervix. AB Miller, G Anderson, J Brisson, J Laidlaw, N Le Pitre, P Malcolmson, ... CMAJ: Canadian Medical Association Journal 145 (10), 1301, 1991 | 219 | 1991 |
| Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. P Hoskins, E Eisenhauer, S Beare, M Roy, P Drouin, G Stuart, P Bryson, ... Journal of clinical oncology 16 (6), 2233-2237, 1998 | 191 | 1998 |
| Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer MJ Piccart, K Bertelsen, G Stuart, J Cassidy, C Mangioni, E Simonsen, ... International Journal of Gynecologic Cancer 13 (Suppl 2), 2003 | 182 | 2003 |
| Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen–Friedenreich) determinant using a synthetic carbohydrate antigen GD MacLean, MB Bowen-Yacyshyn, J Samuel, A Meikle, G Stuart, ... Journal of Immunotherapy 11 (4), 292-305, 1992 | 172 | 1992 |
| The role of the fallopian tube in ovarian cancer AA Tone, S Salvador, SJ Finlayson, AV Tinker, JS Kwon, CH Lee, ... Clin Adv Hematol Oncol 10 (5), 296-306, 2012 | 159 | 2012 |
| An evaluation of routine follow-up of patients treated for endometrial carcinoma AG Shumsky, GCE Stuart, PM Brasher, JG Nation, DI Robertson, ... Gynecologic oncology 55 (2), 229-233, 1994 | 147 | 1994 |
